Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Anti-inflammatory Agents for Breast Cancer

Anti-inflammatory Agents for Breast Cancer Opinion EDITORIAL Case Closed or Is the Jury Still Out? Wendy Y. Chen, MD, MPH; Jennifer A. Ligibel, MD Inflammation is one of the hallmarks of cancer. Preclinical work adjusted hazard ratio, 0.97; 95% CI, 0.80-1.17; log-rank P = .75). demonstrates that inflammation is associated with malig- There was also no difference in overall survival (OS) by group (unadjusted hazard ratio, 0.97; 95% CI, 0.76-1.22; log-rank nant transformation, tumor growth, and the development of metastasis. In observational studies of humans, inflamma- P = .78). Among 1471 patients with COX-2 expression results, tory biomarkers were found there was no association between COX-2 tumor status and the to be associated with an in- effect of celecoxib on DFS or OS. Related article page 1291 creased risk of developing These results were largely consistent with the Cancer Clini- breast cancer and other cancers as well as poor outcomes for cal Trials Group MA.27, in which 1622 patients with breast can- 2,3 individuals who received a diagnosis of early-stage disease. cer were randomly assigned to either celecoxib, 400 mg daily, Observational studies have also found an association be- or placebo. That study also failed to demonstrate improve- tween use of anti-inflammatory agents, such http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Anti-inflammatory Agents for Breast Cancer

JAMA Oncology , Volume 7 (9) – Sep 15, 2021

Loading next page...
 
/lp/american-medical-association/anti-inflammatory-agents-for-breast-cancer-6OWQaFYNmF
Publisher
American Medical Association
Copyright
Copyright 2021 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2021.2056
Publisher site
See Article on Publisher Site

Abstract

Opinion EDITORIAL Case Closed or Is the Jury Still Out? Wendy Y. Chen, MD, MPH; Jennifer A. Ligibel, MD Inflammation is one of the hallmarks of cancer. Preclinical work adjusted hazard ratio, 0.97; 95% CI, 0.80-1.17; log-rank P = .75). demonstrates that inflammation is associated with malig- There was also no difference in overall survival (OS) by group (unadjusted hazard ratio, 0.97; 95% CI, 0.76-1.22; log-rank nant transformation, tumor growth, and the development of metastasis. In observational studies of humans, inflamma- P = .78). Among 1471 patients with COX-2 expression results, tory biomarkers were found there was no association between COX-2 tumor status and the to be associated with an in- effect of celecoxib on DFS or OS. Related article page 1291 creased risk of developing These results were largely consistent with the Cancer Clini- breast cancer and other cancers as well as poor outcomes for cal Trials Group MA.27, in which 1622 patients with breast can- 2,3 individuals who received a diagnosis of early-stage disease. cer were randomly assigned to either celecoxib, 400 mg daily, Observational studies have also found an association be- or placebo. That study also failed to demonstrate improve- tween use of anti-inflammatory agents, such

Journal

JAMA OncologyAmerican Medical Association

Published: Sep 15, 2021

References